Clinical laboratory will support product development and enable patient access to novel test offerings

SYDNEY & AUSTIN, Texas--(BUSINESS WIRE)--#diagnostics--SpeeDx Pty, Ltd. announced the expansion of US based operations and will initiate construction of clinical testing facilities in Austin, Texas. The site will house a range of instrumentation to facilitate clinical trial testing activities in addition to offering innovative diagnostic services.

�Acquisition of this space represents a major milestone in the expansion of our company into the United States,� said Dr Charles Cartwright, SpeeDx Senior Vice President of Clinical Affairs. �Once operational, this facility will enable us to greatly accelerate our product development and clinical trial efforts. We will also seek to bring novel clinical test offerings to US-based customers by leveraging the technological innovations developed by our researchers in Sydney.�

SpeeDx currently offers a range of diagnostic tests for infectious diseases with sales across Europe, Australia, Canada, and the Middle East. With multiple novel technologies in PCR product detection, multiplexing, and quantification, the company is currently engaged in a range of projects that will expand the company�s offerings across a number of disease states. By opening an accredited clinical laboratory in Austin, US-based clinicians and their patients will be able to benefit from these developments and have full access to SpeeDx�s unique pipeline of PCR-based applications.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin, Texas and London, UK, with distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com

Contacts

Madeline O�Donoghue

+61 2 9209 4170

[email protected]